Human papillomavirus in the HIV-infected host: epidemiology and pathogenesis in the antiretroviral era

Curr HIV/AIDS Rep. 2015 Mar;12(1):6-15. doi: 10.1007/s11904-014-0254-4.

Abstract

Human papillomavirus (HPV) infection is associated with essentially all cervical cancers, 80-90 % of anal cancers, and a high proportion of oropharyngeal, vaginal, penile, and vulvar cancers. Malignancy is preceded by the development of precancerous lesions termed high-grade squamous intraepithelial lesions (HSIL). Men and women with human immunodeficiency virus (HIV) infection are at high risk of HPV-related malignancies. The incidence of anal cancer in particular has markedly risen during the antiretroviral era due to the increased longevity of patients with HIV and the absence of anal malignancy screening programs. HIV infection may facilitate initial HPV infection by disrupting epithelial cell tight junctions. Once infection is established, HIV may promote HSIL development via the up-regulation of HPV oncogene expression and impairment of the immune response needed to clear the lesion. HIV-infected women should be screened for cervical HSIL and cancer, and HIV-infected men and women should be considered for anal screening programs.

Publication types

  • Review

MeSH terms

  • Anti-Retroviral Agents / therapeutic use
  • Anus Neoplasms / drug therapy
  • Anus Neoplasms / epidemiology*
  • Anus Neoplasms / virology
  • Carcinoma in Situ / drug therapy
  • Carcinoma in Situ / epidemiology*
  • Carcinoma in Situ / virology
  • Female
  • HIV / pathogenicity*
  • HIV Infections / drug therapy
  • HIV Infections / epidemiology*
  • HIV Infections / virology
  • Humans
  • Male
  • Papillomaviridae / pathogenicity*
  • Papillomavirus Infections / drug therapy
  • Papillomavirus Infections / epidemiology*
  • Papillomavirus Infections / virology
  • Uterine Cervical Neoplasms / drug therapy
  • Uterine Cervical Neoplasms / epidemiology*
  • Uterine Cervical Neoplasms / virology

Substances

  • Anti-Retroviral Agents